Oncology Precision Medicine Market.pdf

1
All rights reserved at BIS Research Inc.
O
n
c
o
l
o
g
y
P
r
e
c
i
s
i
o
n
M
e
d
i
c
i
n
e
M
a
r
k
e
t
Focus on Ecosystem and Application,
Analysis and Forecast: 2020-2031
March 2022
Oncology
Precision
Medicine Market -
A Global and
Regional Analysis
Table of Content

2
O
n
c
o
l
o
g
y
P
r
e
c
i
s
i
o
n
M
e
d
i
c
i
n
e
M
a
r
k
e
t
BIS Research is a leading market intelligence and technology research company. BIS Research publishes in-
depth market intelligence reports focusing on the market estimations, technology analysis, emerging high-
growth applications, deeply segmented granular country-level market data and other important market
parameters useful in the strategic decision making for senior management. BIS Research provides multi-client
reports, company profiles, databases, and custom research services.
Copyright © 2022 BIS Research Inc.
All Rights Reserved. This document contains highly confidential information and is the sole property of BIS
Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all contents of this
document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people
or organization concerned. It may not be accessed by or offered whether for sale or otherwise to any third
party.

3
O
n
c
o
l
o
g
y
P
r
e
c
i
s
i
o
n
M
e
d
i
c
i
n
e
M
a
r
k
e
t
Table of Content
Executive Summary..........................................................................27
1. Markets .....................................................................................40
1.1 Industry Outlook..............................................................................................41
1.1.1 Introduction .................................................................................................41
1.2 Evolution of Precision Medicine for Cancer Management and
Treatment .........................................................................................................42
1.3 Applications of Precision Medicine in Oncology..........................................43
1.3.1 Identifying Genetic Mutations and Risks of Cancer Through
Precision Diagnostics.................................................................................43
1.3.2 Promising Technological Developments Supporting Precision
Oncology......................................................................................................45
1.3.2.1 Low-Throughput Genomic Sequencing to High-Throughput Genomic
Sequencing........................................................................................................ 45
1.3.2.2 Multicell Hybrid Detection to Single-Cell Precision Detection............................ 45
1.3.2.3 Advancing Applications of ctDNA Detection Technology .................................. 45
1.3.2.4 CRISPR/Cas Technology .................................................................................. 46
1.4 Impact of COVID-19 Pandemic on Global Oncology Precision
Medicine Market...............................................................................................46
1.4.1 Disruption of Oncology Precision Medicine Due to COVID-19................46
1.4.2 COVID-19 Affecting Supply Chain of Oncology Precision Medicine-
Based Therapies..........................................................................................48
1.4.3 Interruption in Research and Clinical Development and Commercial
Operation .....................................................................................................49
1.4.3.1 Research and Clinical Development.................................................................. 49
1.4.4 Commercial Operation and Access ...........................................................49
1.4.5 Navigating Crisis Recovery and Looking to the Future...........................50
1.5 Market Dynamics .............................................................................................51
1.5.1 Impact Analysis ...........................................................................................52

4
O
n
c
o
l
o
g
y
P
r
e
c
i
s
i
o
n
M
e
d
i
c
i
n
e
M
a
r
k
e
t
1.5.2 Market Drivers .............................................................................................53
1.5.2.1 Increasing Incidence of Cancer Globally ........................................................... 53
1.5.2.2 Decreasing Trial and Error-Based Drug Prescription Through
Pharmacogenomics........................................................................................... 55
1.5.2.3 Increasing Usage of Predictive Biomarker for Cancer Diagnostics ................... 55
1.5.2.4 Rapid Technological Advancements related to Oncology Precision
Medicine ............................................................................................................ 56
1.5.2.5 Decreasing Cost and Increase in the Output of Genomic Sequencing ............. 57
1.5.3 Restraints.....................................................................................................58
1.5.3.1 Large Scale Data Integration, Analysis, and Establishment of Secure Data
Libraries............................................................................................................. 58
1.5.3.2 Inadequate Reimbursement Scenario for Precision Medicine........................... 59
1.5.3.3 Barriers in the Advancement of Precision Medicine .......................................... 60
1.5.3.3.1 Regulatory Barriers .................................................................................................. 60
1.5.3.4 Lack of Expertise, Education, and Awareness for Precision Medicine
Implementation .................................................................................................. 61
1.6 Market Opportunities.......................................................................................62
1.6.1 Unprecedented Improvements in Disease Modelling via In-Silico,
In-Vitro, and In-Vivo Methods.....................................................................62
1.6.2 Expansion into the Emerging Markets ......................................................62
1.6.3 Rising Number of Initiatives for Precision Oncology Research..............63
1.7 Competitive Landscape...................................................................................64
1.7.1 Acquisitions.................................................................................................66
1.7.2 Synergistic Activities ..................................................................................66
1.7.3 Product Launches, Approvals, and Upgradations ...................................67
1.7.4 Business Expansion ...................................................................................69
1.7.5 Market Share Analysis ................................................................................69
1.7.6 Growth Share Analysis ...............................................................................71
1.7.6.1 Growth Share Analysis (by Application) ............................................................ 71

5
O
n
c
o
l
o
g
y
P
r
e
c
i
s
i
o
n
M
e
d
i
c
i
n
e
M
a
r
k
e
t
1.7.6.2 Growth Share Analysis (by Ecosystem) ............................................................ 72
1.8 Industry Insights..............................................................................................74
1.8.1 Legal and Regulatory Framework and Requirements..............................74
1.8.2 North America..............................................................................................74
1.8.2.1 Regulatory Requirements in U.S. ...................................................................... 74
1.8.3 Europe..........................................................................................................77
1.8.3.1 U.K..................................................................................................................... 79
1.8.3.1.1 Regulatory Requirements in U.K. ............................................................................ 79
1.8.3.1.1.1 The Cancer Plan............................................................................................... 79
1.8.4 Asia-Pacific..................................................................................................80
1.9 Legal Requirements and Framework by MHLW............................................80
1.10 Legal Requirement and Framework by NMPA ..............................................80
1.11 Patent Analysis................................................................................................81
1.11.1 Patent Filing Trend......................................................................................81
1.11.1.1 Patent Analysis (by Region) .............................................................................. 82
1.11.1.2 Patent Analysis (by Country) ............................................................................. 83
2. Global Oncology Precision Medicine Market, by Ecosystem, $
Million, 2020-2031......................................................................84
2.1 Overview...........................................................................................................85
2.1.1 Precision Therapeutics...............................................................................85
2.1.1.1 Clinical Trials ..................................................................................................... 87
2.1.1.2 Biomarker Testing.............................................................................................. 88
2.1.1.3 Drug Discovery and Research........................................................................... 88
2.1.1.4 Gene Therapy.................................................................................................... 90
2.1.1.5 Cell Therapy ...................................................................................................... 91
2.1.2 Applied Sciences.........................................................................................92
2.1.2.1 Genomics........................................................................................................... 92
2.1.2.1.1 Polymerase Chain Reaction (PCR) ......................................................................... 94

6
O
n
c
o
l
o
g
y
P
r
e
c
i
s
i
o
n
M
e
d
i
c
i
n
e
M
a
r
k
e
t
2.1.2.1.2 Precision Medicine Next-Generation Sequencing ................................................... 94
2.1.2.1.3 Genome Editing ....................................................................................................... 96
2.1.2.1.4 Other Technologies.................................................................................................. 96
2.1.2.2 Pharmacogenomics........................................................................................... 97
2.1.2.3 Other Applied Sciences ..................................................................................... 99
2.1.3 Digital Health and Information Technology ............................................100
2.1.3.1 Clinical Decision Support System (CDSS) ...................................................... 101
2.1.3.2 Big Data Analytics............................................................................................ 102
2.1.3.3 IT Infrastructure ............................................................................................... 104
2.1.3.4 Genomics Informatics...................................................................................... 105
2.1.3.5 In-Silico Informatics ......................................................................................... 106
2.1.3.6 Mobile Health................................................................................................... 107
2.1.4 Precision Diagnostics...............................................................................108
2.1.4.1 Molecular Diagnostics (MDx)........................................................................... 110
2.1.4.2 Medical Imaging............................................................................................... 111
3. Global Oncology Precision Medicine Market, by Application, $
Million, 2020-2031....................................................................113
3.1 Overview.........................................................................................................114
3.1.1 Solid Tumor ...............................................................................................114
3.1.1.1 Breast Cancer.................................................................................................. 115
3.1.1.2 Lung Cancer .................................................................................................... 116
3.1.1.3 Colorectal Cancer............................................................................................ 117
3.1.1.4 Prostate Cancer............................................................................................... 118
3.1.1.5 Cervical Cancer ............................................................................................... 119
3.1.1.6 Other Cancer ................................................................................................... 120
3.1.2 Hematological Malignancies (HMs)..........................................................121
3.1.2.1 Leukemia ......................................................................................................... 122
3.1.2.2 Lymphoma....................................................................................................... 123
3.1.2.3 Myeloma or Multiple Myeloma (MM)................................................................ 124

7
O
n
c
o
l
o
g
y
P
r
e
c
i
s
i
o
n
M
e
d
i
c
i
n
e
M
a
r
k
e
t
3.1.2.4 Other Hematological Malignancies.................................................................. 125
4. Global Oncology Precision Medicine Market, by Regions, $
Million, 2020-2031....................................................................127
4.1 Overview.........................................................................................................128
4.2 North America................................................................................................130
4.2.1 Key Competitors (by Ecosystem) ............................................................130
4.2.2 North America Oncology Precision Medicine Market (by
Application)................................................................................................132
4.2.3 Key Trends in the North America Oncology Precision Medicine
Market.........................................................................................................133
4.2.4 U.S. .............................................................................................................133
4.2.5 Canada .......................................................................................................135
4.3 Europe ............................................................................................................138
4.3.2 Europe Oncology Precision Medicine Market (by Application).............140
4.3.3 Key Trends of Europe Oncology Precision Medicine Market................140
4.3.4 Germany.....................................................................................................141
4.3.5 U.K. .............................................................................................................142
4.3.6 France.........................................................................................................143
4.3.7 Italy .............................................................................................................145
4.3.8 Spain...........................................................................................................146
4.3.9 Rest-of-Europe...........................................................................................148
4.4 Asia-Pacific ....................................................................................................150
4.4.2 Asia-Pacific Oncology Precision Medicine Market (by Application).....152
4.4.3 Key Trends in the Asia-Pacific Oncology Precision Medicine Market
....................................................................................................................153
4.4.4 China ..........................................................................................................154
4.4.5 India............................................................................................................155

8
O
n
c
o
l
o
g
y
P
r
e
c
i
s
i
o
n
M
e
d
i
c
i
n
e
M
a
r
k
e
t
4.4.6 Japan..........................................................................................................156
4.4.7 Australia.....................................................................................................157
4.4.8 South Korea ...............................................................................................158
4.4.9 Rest-of-Asia-Pacific...................................................................................159
4.5 Latin America (LATAM) .................................................................................160
4.5.2 Latin America Oncology Precision Medicine Market (by
Application)................................................................................................162
4.5.3 Key Trends in the Latin America Oncology Precision Medicine
Market.........................................................................................................162
4.5.4 Brazil...........................................................................................................163
4.5.5 Mexico ........................................................................................................164
4.5.6 Rest-of-Latin America ...............................................................................164
4.6 Rest-of-the-World (RoW)...............................................................................166
4.6.2 Rest-of-the-World Oncology Precision Medicine Market (by
Application)................................................................................................167
4.6.3 Key Trends in the Rest-of-the-World Oncology Precision Medicine
Market.........................................................................................................168
5. Markets - Competitive Benchmarking & Company Profiles ......169
5.1 Overview.........................................................................................................170
5.2 Agilent Technologies, Inc. ............................................................................171
5.2.1 Company Overview ...................................................................................171
5.2.2 Role of Agilent Technologies, Inc. in the Global Oncology Precision
Medicine Market.........................................................................................171
5.2.3 Key Competitors of the Company............................................................172
5.2.4 Financials...................................................................................................172
5.2.5 Key Insights About Financial of the Company .......................................174
5.2.6 Corporate Strategies.................................................................................175

9
O
n
c
o
l
o
g
y
P
r
e
c
i
s
i
o
n
M
e
d
i
c
i
n
e
M
a
r
k
e
t
5.2.6.1 Mergers and Acquisitions ................................................................................ 175
5.2.6.2 Synergistic Activities........................................................................................ 175
5.2.6.3 Business Expansion and Funding ................................................................... 175
5.2.6.4 Product Launches and Upgradation ................................................................ 176
5.2.7 SWOT Analysis..........................................................................................177
5.3 Bio-Rad Laboratories, Inc. ............................................................................178
5.3.2 Role of Bio-Rad Laboratories, Inc. in the Global Oncology Precision
Medicine Market.........................................................................................178
5.3.4 Financials...................................................................................................179
5.3.5 Key Insights About Financial Health of the Company ...........................181
5.3.6.1 Product Launches and upgradation................................................................. 182
5.3.7 SWOT Analysis..........................................................................................183
5.4 Illumina, Inc....................................................................................................184
5.4.2 Role of Illumina, Inc. in the Global Oncology Precision Medicine
Market.........................................................................................................184
5.4.4 Financials...................................................................................................185
5.4.6.1 Mergers and Acquisition .................................................................................. 187
5.4.7 SWOT Analysis..........................................................................................189
5.5 Pacific Biosciences of California, Inc. .........................................................190

10
O
n
c
o
l
o
g
y
P
r
e
c
i
s
i
o
n
M
e
d
i
c
i
n
e
M
a
r
k
e
t
5.5.2 Role of Pacific Biosciences of California, Inc. in the Global
Oncology Precision Medicine Market......................................................190
5.5.4 Financials...................................................................................................192
5.5.7 SWOT Analysis..........................................................................................196
5.6 PerkinElmer Inc..............................................................................................197
5.6.2 Role of PerkinElmer Inc. in the Global Oncology Precision Medicine
Market.........................................................................................................197
5.6.4 Financials...................................................................................................198
5.6.6.1 Mergers and Acquisition: ................................................................................. 201
5.6.7 SWOT Analysis..........................................................................................202
5.7 QIAGEN...........................................................................................................203
5.7.2 Role of QIAGEN in the Global Oncology Precision Medicine Market
....................................................................................................................203

11
O
n
c
o
l
o
g
y
P
r
e
c
i
s
i
o
n
M
e
d
i
c
i
n
e
M
a
r
k
e
t
5.7.4 Financials...................................................................................................204
5.7.7 SWOT Analysis..........................................................................................209
5.8 Thermo Fisher Scientific Inc.........................................................................210
5.8.2 Role of Thermo Fisher Scientific Inc. in the Global Oncology
Precision Medicine Market .......................................................................210
5.8.4 Financials...................................................................................................211
5.8.7 SWOT Analysis..........................................................................................216
5.9 BGI Group.......................................................................................................217
5.9.2 Role of BGI Group in the Global Oncology Precision Medicine
Market.........................................................................................................217

12
O
n
c
o
l
o
g
y
P
r
e
c
i
s
i
o
n
M
e
d
i
c
i
n
e
M
a
r
k
e
t
5.9.5 SWOT Analysis..........................................................................................219
5.10 ASURAGEN, INC............................................................................................220
5.10.2 Role of ASURAGEN, INC. in Global Oncology Precision Medicine
Market.........................................................................................................220
5.10.5 SWOT Analysis..........................................................................................222
5.11 Almac Group Ltd............................................................................................223
5.11.2 Role of Almac Group Ltd. in Global Oncology Precision Medicine
Market.........................................................................................................223
5.11.5 SWOT Analysis..........................................................................................225
5.12 MDxHealth ......................................................................................................226
5.12.2 Role of MDxHealth in the Global Oncology Precision Medicine
Market.........................................................................................................226

13
O
n
c
o
l
o
g
y
P
r
e
c
i
s
i
o
n
M
e
d
i
c
i
n
e
M
a
r
k
e
t
5.12.4 Financials...................................................................................................227
5.12.7 SWOT Analysis..........................................................................................231
5.13 Abbott Laboratories ......................................................................................232
5.13.2 Role of Abbott Laboratories in the Global Oncology Precision
Medicine Market.........................................................................................232
5.13.4 Financials...................................................................................................233
5.13.5.4 Product launches and Upgradation ................................................................. 236
5.13.6 SWOT Analysis..........................................................................................237
5.14 F. Hoffmann-La Roche Ltd............................................................................238
5.14.2 Role of F. Hoffman-LA Roche Ltd in the Global Oncology Precision
Medicine Market.........................................................................................238
5.14.4 Financials...................................................................................................239

14
O
n
c
o
l
o
g
y
P
r
e
c
i
s
i
o
n
M
e
d
i
c
i
n
e
M
a
r
k
e
t
5.14.6 SWOT Analysis..........................................................................................244
5.15 Gilead Sciences, Inc. .....................................................................................245
5.15.2 Role of Gilead Sciences, Inc. in the Global Oncology Precision
Medicine Market.........................................................................................245
5.15.4 Financials...................................................................................................246
5.15.6 SWOT Analysis..........................................................................................248
5.16 Myriad Genetics, Inc......................................................................................249
5.16.2 Role of Myriad Genetics, Inc. in the Global Oncology Precision
Medicine Market.........................................................................................249
5.16.4 Financials...................................................................................................250
5.16.7 SWOT Analysis..........................................................................................254
5.17 OPKO Health, Inc...........................................................................................255

15
O
n
c
o
l
o
g
y
P
r
e
c
i
s
i
o
n
M
e
d
i
c
i
n
e
M
a
r
k
e
t
5.17.2 Role of OPKO Health, Inc. in the Global Oncology Precision
Medicine Market.........................................................................................255
5.17.4 Financials...................................................................................................256
5.17.6 SWOT Analysis..........................................................................................260
5.18 Quest Diagnostics Incorporated ..................................................................261
5.18.2 Role of Quest Diagnostics Incorporated in the Global Oncology
Precision Medicine Market .......................................................................261
5.18.4 Financials...................................................................................................262
5.18.5.2 Synergistics Activities ...................................................................................... 263
5.18.6 SWOT Analysis..........................................................................................264
5.19 Novartis AG....................................................................................................265
5.19.2 Role of Novartis AG in the Global Oncology Precision Medicine
Market.........................................................................................................265
5.19.4 Financials...................................................................................................266

16
O
n
c
o
l
o
g
y
P
r
e
c
i
s
i
o
n
M
e
d
i
c
i
n
e
M
a
r
k
e
t
5.19.6 SWOT Analysis..........................................................................................268
5.20 Emerging Companies....................................................................................269
5.20.1 Prelude Therapeutics................................................................................269
5.20.1.1 Company Overview ......................................................................................... 269
5.20.2 AceTech .....................................................................................................269
5.20.3 Flatiron .......................................................................................................270
5.20.4 Biosplice Therapeutics, Inc. .....................................................................270

17
O
n
c
o
l
o
g
y
P
r
e
c
i
s
i
o
n
M
e
d
i
c
i
n
e
M
a
r
k
e
t
List of Figures
Figure 1: Overall Deaths Due to Key Cancer Causes, Million, 2012-2019
Figure 2: Global Oncology Precision Medicine Market, $Million, 2020-2031
Figure 3: Global Oncology Precision Medicine Market, Market Dynamics
Figure 4: Share of Key Developments and Strategies, January 2018-January 2022
Figure 5: Global Oncology Precision Medicine Market (by Ecosystem), $Million, 2020 Vs. 2031
Figure 6: Global Oncology Precision Medicine Market (by Application), $Million, 2020 Vs. 2031
Figure 7: Global Oncology Precision Medicine Market (by Region), 2020 Vs. 2031
Figure 8: Global Oncology Precision Medicine Market Research Methodology
Figure 9: Share of Total Number of Companies Profiled
Figure 10: Global Oncology Precision Medicine Market: Segmentation
Figure 11: Global Oncology Precision Medicine Market, $Million, 2020-2031
Figure 12: Evolution of Precision Medicine Technology
Figure 13: Molecular Diagnostics in Oncology
Figure 14: Number of Cancer Cases Diagnosed in the Netherlands (January 3, 2020 - April 5 2020)
Figure 15: Pre-COVID-19 and Post-COVID-19 Scenario of Global Oncology Precision Medicine
Market, 2017-2025
Figure 16: Areas of Disruption in Clinical Development
Figure 17: Measure to Navigate Crisis Recovery
Figure 18: Global Oncology Precision Medicine Market - Market Dynamics
Figure 19: Estimated Tracheal, Bronchus and Lung Cancer Incidences (Region-Wise), 2020 and
2030(E)
Figure 20: Estimated Cancer Mortality (Region-Wise), 2020
Figure 21: Decreasing Cost and Increasing Output of Genome Sequencing, 2009-2025
Figure 22: Share of Key Developments and Strategies, January 2018-January 2022
Figure 23: Share of Acquisitions (by Company), January 2018-January 2022
Figure 24: Synergistic Activities Share (by Company), January 2018-January 2022
Figure 25: Product Launches and Approvals (by Company), January 2018–January 2022
Figure 26: Share of Business Expansion (by Company), January 2018-January 2022
Figure 27: Market Share Analysis for Global Oncology Precision Medicine Market, $Million, 2020

18
O
n
c
o
l
o
g
y
P
r
e
c
i
s
i
o
n
M
e
d
i
c
i
n
e
M
a
r
k
e
t
Figure 28: Growth Share Analysis of Global Oncology Precision Medicine Market (by Application),
2021-2031
Figure 29: Growth Share Analysis of Global Oncology Precision Medicine Market (by Ecosystem),
2021-2031
Figure 30: FDA Guidelines for CDx Approval
Figure 31: Year-Wise Analysis of Patents Related to Oncology Precision Medicine, January 2018-
January 2022
Figure 32: Region-Wise Analysis of Patents Related to Oncology Precision Medicine, January 2018
- January 2022
Figure 33: Country-Wise Analysis of Patents Related to Oncology Precision Medicine, January
2018 - January 2022
Figure 34: Share of Global Oncology Precision Medicine Market (by Ecosystem), $Million, 2020 and
2031
Figure 35: Global Oncology Precision Medicine Market (Precision Therapeutics), $Million, 2020-
2031
Figure 36: Global Oncology Precision Medicine Market (Clinical Trials), $Million, 2020-2031
Figure 37: Global Oncology Precision Medicine Market (Biomarker Testing), $Million, 2020-2031
Figure 38: Global Oncology Precision Medicine Market (Drug Discovery and Research), $Million,
2020-2031
Figure 39: Global Oncology Precision Medicine Market (Gene Therapy), $Million, 2020-2031
Figure 40: Global Oncology Precision Medicine Market (Cell Therapy), $Million, 2020-2031
Figure 41: Global Oncology Precision Medicine Market (Applied Sciences), $Million, 2020-2031
Figure 42: Global Oncology Precision Medicine Market (Genomics), $Million, 2020-2031
Figure 43: Global Oncology Precision Medicine Market (PCR), $Million, 2020-2031
Figure 44: Global Oncology Precision Medicine Market (Precision Medicine NGS), $Million, 2020-
2031
Figure 45: Global Oncology Precision Medicine Market (Genome Editing), $Million, 2020-2031
Figure 46: Global Oncology Precision Medicine Market (Other Technologies) $Million, 2020-2031
Figure 47: Global Oncology Precision Medicine Market (Pharmacogenomics), $Million, 2020-2031
Figure 48: Global Oncology Precision Medicine Market (Other Applied Sciences), $Million, 2020-
2031
Figure 49: Global Oncology Precision Medicine Market (Digital Health and Information Technology),
$Million, 2020-2031
Figure 50: Global Oncology Precision Medicine Market (CDSS), $Million, 2020-2031
Figure 51: Global Oncology Precision Medicine Market (Big Data Analytics), $Million, 2020-2031

19
O
n
c
o
l
o
g
y
P
r
e
c
i
s
i
o
n
M
e
d
i
c
i
n
e
M
a
r
k
e
t
Figure 52: Global Oncology Precision Medicine Market (IT Infrastructure), $Million, 2020-2031
Figure 53: Global Oncology Precision Medicine Market (Genomics Informatics), $Million, 2020-2031
Figure 54: Global Oncology Precision Medicine Market (In-Silico Informatics), $Million, 2020-2031
Figure 55: Global Oncology Precision Medicine Market (Mobile Health), $Million, 2020-2031
Figure 56: Global Oncology Precision Medicine Market (Precision Diagnostics), $Million, 2020-2031
Figure 57: Global Oncology Precision Medicine Market (Molecular Diagnostics), $Million, 2020-
2031
Figure 58: Global Oncology Precision Medicine Market (Medical Imaging), $Million, 2020-2031
Figure 59: Global Oncology Precision Medicine Market (by Application), $Million, 2020 and 2031
Figure 60: Global Oncology Precision Medicine Market (Solid Tumor), $Million, 2020-2031
Figure 61: Global Oncology Precision Medicine Market (Breast Cancer), $Million, 2020-2031
Figure 62: Global Oncology Precision Medicine Market (Lung Cancer), $Million, 2020-2031
Figure 63: Global Oncology Precision Medicine Market (Colorectal Cancer), $Million, 2020-2031
Figure 64: Global Oncology Precision Medicine Market (Prostate Cancer), $Million, 2020-2031
Figure 65: Global Oncology Precision Medicine Market (Cervical Cancer), $Million, 2020-2031
Figure 66: Global Oncology Precision Medicine Market (Other Cancer), $Million, 2020-2031
Figure 67: Global Oncology Precision Medicine Market (Hematological Malignancies), $Million,
2020-2031
Figure 68: Global Oncology Precision Medicine Market (Leukemia), $Million, 2020-2031
Figure 69: Global Oncology Precision Medicine Market (Lymphoma), $Million, 2020-2031
Figure 70: Global Oncology Precision Medicine Market (Myeloma), $Million, 2020-2031
Figure 71: Global Oncology Precision Medicine Market (Other Hematological Malignancies),
$Million, 2020-2031
Figure 72: Global Oncology Precision Medicine Market (by Region), 2020-2031
Figure 73: Share of North America Oncology Precision Medicine Market (by Country), $Million,
2020 and 2031
Figure 74: North America: Market Dynamics
Figure 75: North America Oncology Precision Medicine Market (by Application), $Million, 2020 and
2031
Figure 76: U.S. Oncology Precision Medicine Market, $Million, 2020-2031
Figure 77: Canada Oncology Precision Medicine Market, $Million, 2020-2031
Figure 78: Europe Oncology Precision Medicine Market (by Country), $Million, 2020 and 2031

20
O
n
c
o
l
o
g
y
P
r
e
c
i
s
i
o
n
M
e
d
i
c
i
n
e
M
a
r
k
e
t
Figure 79: Europe: Market Dynamics
Figure 80: Europe Oncology Precision Medicine Market (by Application), $Million, 2020 and 2031
Figure 81: Germany Oncology Precision Medicine Market, $Million, 2020-2031
Figure 82: U.K. Oncology Precision Medicine Market, Million, 2020-2031
Figure 83: France Oncology Precision Medicine Market, $Million, 2020-2031
Figure 84: Italy Oncology Precision Medicine Market, $Million, 2020-2031
Figure 85: Spain Oncology Precision Medicine Market, $Million, 2020-2031
Figure 86: Rest-of-Europe Oncology Precision Medicine Market, $Million, 2020-2031
Figure 87: APAC: Market Dynamics
Figure 88: Asia-Pacific Oncology Precision Medicine Market (by Country), $Million, 2020 and 2031
Figure 89: Asia-Pacific Oncology Precision Medicine Market (by Application), $Million, 2020 and
2031
Figure 90: China Oncology Precision Medicine Market, $Million, 2020-2031
Figure 91: India Oncology Precision Medicine Market, $Million, 2020-2031
Figure 92: Japan Oncology Precision Medicine Market, $Million, 2020-2031
Figure 93: Australia Oncology Precision Medicine Market, Million, 2020-2031
Figure 94: South Korea Oncology Precision Medicine Market, Million, 2020-2031
Figure 95: Rest-of-Asia-Pacific Oncology Precision Medicine Market, $Million, 2020-2031
Figure 96: LATAM: Market Dynamics
Figure 97: Latin America Oncology Precision Medicine Market (by Country), $Million, 2020-2031
Figure 98: Latin America Oncology Precision Medicine Market (by Application), $Million, 2020 and
2031
Figure 99: Brazil Oncology Precision Medicine Market, $Million, 2020-2031
Figure 100: Mexico Oncology Precision Medicine Market, Million, 2020-2031
Figure 101: Rest-of-Latin America Oncology Precision Medicine Market, $Million, 2020-2031
Figure 102: Rest-of-the-World Oncology Precision Medicine Market, $Million, 2020-2031
Figure 103: Rest-of-the-World Oncology Precision Medicine Market (by Application), $Million, 2020
and 2031
Figure 104: Share of Key Company Profiled (22)
Figure 105: Agilent Technologies, Inc.: Product Portfolio
Figure 106: Agilent Technologies, Inc.: Overall Financials, $Million, 2019-2021

21
O
n
c
o
l
o
g
y
P
r
e
c
i
s
i
o
n
M
e
d
i
c
i
n
e
M
a
r
k
e
t
Figure 107: Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 108: Agilent Technologies, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 109: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 110: Agilent Technologies, Inc.: SWOT Analysis
Figure 111: Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 112: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2018-2020
Figure 113: Bio-Rad Laboratories, Inc.: Revenue (by Business Segment), $Million, 2018-2020
Figure 114: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 115: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 116: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 117: Illumina, Inc.: Product Portfolio
Figure 118: Illumina, Inc.: Overall Financials, $Million, 2018-2020
Figure 119: Illumina, Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 120: Illumina, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 121: Illumina, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 122: Illumina, Inc.: SWOT Analysis
Figure 123: Pacific Biosciences of California, Inc.: Product Portfolio
Figure 124: Pacific Biosciences of California, Inc.: Overall Financials, $Million, 2018-2020
Figure 125: Pacific Biosciences of California, Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 126: Pacific Biosciences of California, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 127: Pacific Biosciences of California, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 128: Pacific Biosciences of California, Inc.: SWOT Analysis
Figure 129: PerkinElmer Inc.: Product Portfolio
Figure 130: PerkinElmer Inc.: Overall Financials, $Million, 2018-2020
Figure 131: PerkinElmer Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 132: PerkinElmer Inc: Revenue (by Region), $Million, 2018-2020
Figure 133: PerkinElmer Inc. R&D Expenditure, $Million, 2018-2020
Figure 134: PerkinElmer Inc.: SWOT Analysis
Figure 135: QIAGEN: Portfolio

22
O
n
c
o
l
o
g
y
P
r
e
c
i
s
i
o
n
M
e
d
i
c
i
n
e
M
a
r
k
e
t
Figure 136: QIAGEN: Overall Financials, $Million, 2018-2020
Figure 137: QIAGEN: Revenue (by Segment), $Million, 2018-2020
Figure 138: QIAGEN: Revenue (by Region), $Million, 2018-2020
Figure 139: QIAGEN: R&D Expenditure, $Million, 2018-2020
Figure 140: QIAGEN: SWOT Analysis
Figure 141: Thermo Fisher Scientific, Inc.: Product Portfolio
Figure 142: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2018-2020
Figure 143: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), $Million, 2018-2020
Figure 144: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2018-2020
Figure 145: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2018-2020
Figure 146: Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 147: BGI Product Portfolio
Figure 148: BGI Group: SWOT Analysis
Figure 149: ASURAGEN, INC.: Overall Product Offerings
Figure 150: ASURAGEN,INC.: SWOT Analysis
Figure 151: Almac Group Ltd.: Overall Product Offerings
Figure 152: Almac Group Ltd.: SWOT Analysis
Figure 153: MDxHealth: Service Portfolio
Figure 154: MDxHealth: Overall Financials, $Million, 2018-2020
Figure 155: MDxHealth: Revenue (by Segment), $Million, 2018-2020
Figure 156: MDxHealth: Revenue (by Region), $Million, 2018-2020
Figure 157: MDxHealth: R&D Expenditure, $Million, 2018-2020
Figure 158: MdxHealth: SWOT Analysis
Figure 159: Abbott Laboratories: Overall Product Offerings
Figure 160: Abbott Laboratories: Overall Financials, $Million, 2018-2020
Figure 161: Abbott Laboratories: Net Revenue (by Business Segment), $Million, 2018-2020
Figure 162: Abbott Laboratories: Net Revenue (by Region), $Million, 2018-2020
Figure 163: Abbott Laboratories: R&D Expenditure, $Million, 2018-2020
Figure 164: Abbott Laboratories: SWOT Analysis

23
O
n
c
o
l
o
g
y
P
r
e
c
i
s
i
o
n
M
e
d
i
c
i
n
e
M
a
r
k
e
t
Figure 165: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 166: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021
Figure 167: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2019-2021
Figure 168: F. Hoffmann-La Roche Ltd: Revenue (by Region), $Million, 2019-2021
Figure 169: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021
Figure 170: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 171: Gilead Sciences, Inc.: Overall Product Portfolio
Figure 172: Gilead Sciences, Inc.: Overall Financials, $Million, 2018-2020
Figure 173: Gilead Sciences, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 174: Gilead Sciences, Inc.: SWOT Analysis
Figure 175: Myriad Genetics, Inc.: Product Portfolio
Figure 176: Myriad Genetics, Inc.: Overall Financials, $Million, 2018-2020
Figure 177: Myriad Genetics, Inc.: Revenue (by Business Segment), $Million, 2018-2020
Figure 178: Myriad Genetics, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 179: Myriad Genetics, Inc.: SWOT Analysis
Figure 180: OPKO Health, Inc.: Overall Product Portfolio
Figure 181: OPKO Health, Inc.: Overall Financials, $Million, 2018-2020
Figure 182: OPKO Health, Inc: Net Revenue (by Business Segment), $Million, 2018-2020
Figure 183: OPKO Health, Inc.: Net Revenue (by Region), $Million, 2018-2020
Figure 184: OPKO Health, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 185: OPKO Health, Inc.: SWOT Analysis
Figure 186: Quest Diagnostics Incorporated: Overall Product Offerings
Figure 187: Quest Diagnostics Incorporated: Overall Financials, $Million, 2018-2020
Figure 188: Quest Diagnostics Incorporated: Revenue (by Business Segment), $Million, 2018-2020
Figure 189: Quest Diagnostics Incorporated: SWOT Analysis
Figure 190: Novartis AG: Overall Product Portfolio
Figure 191: Novartis AG: Overall Financials, $Million, 2019-2021
Figure 192: Novartis AG: Revenue (by Business Segment), $Million, 2019-2021
Figure 193: Novartis AG: SWOT Analysis

24
O
n
c
o
l
o
g
y
P
r
e
c
i
s
i
o
n
M
e
d
i
c
i
n
e
M
a
r
k
e
t
List of Tables
Table 1: Estimated New Cancer Cases (by Type) in U.S., 2022
Table 2: Potential Usage of Biomarkers in Cancer Diagnostics
Table 3: List of Initiatives for Precision Oncology Research in 2018
Table 4: List of Few FDA-Approved Pharmacogenomics Biomarkers in Drug Labeling
Table 5: Estimated New Cancer Cases and Deaths in the U.S., 2020
Table 6: Key Competitors of North America Oncology Precision Medicine (by Ecosystem), 2020
Table 7: Key Competitors of Europe Oncology Precision Medicine (by Ecosystem), 2020
Table 8: Key Competitors of Asia-Pacific Oncology Precision Medicine (by Ecosystem), 2020
Table 9: Key Competitors of Latin America Oncology Precision Medicine (by Ecosystem), 2020
Table 10: Key Competitors of Rest-of-the-World Oncology Precision Medicine (by Ecosystem), 2020
Table 11: BIS Insight for Prelude Therapeutics
Table 12: BIS Insight for AceTech
Table 13: BIS Insight for Flatiron
Table 14: BIS Insight for Biosplice Therapeutics, Inc.

25
O
n
c
o
l
o
g
y
P
r
e
c
i
s
i
o
n
M
e
d
i
c
i
n
e
M
a
r
k
e
t
BIS Research Offerings:
We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s
digital age. We have a vision to be a leading and a preferred knowledge partner for corporates and institutions
worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other
innovative solutions.
Know More Know More
Know More
Know More

26
O
n
c
o
l
o
g
y
P
r
e
c
i
s
i
o
n
M
e
d
i
c
i
n
e
M
a
r
k
e
t
Disclaimer
BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to
orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth.
This document and its contents are confidential and may not be further distributed, published or reproduced,
in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS
Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly
through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information
to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce
Information in legal proceedings.
Market reports are based on expectations, estimates and projections as of the date such information is
available. Any recommendation contained in this report may not be suitable for all investors or businesses.
The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while
considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to
market fluctuations and business, economic and competitive uncertainties and contingencies.
For more details regarding permission, please contact us:
Email: sales@bisresearch.com
Tel: +1 510 404 8135

27
O
n
c
o
l
o
g
y
P
r
e
c
i
s
i
o
n
M
e
d
i
c
i
n
e
M
a
r
k
e
t
BIS RESEARCH INC.
39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686
E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135
Global Delivery Center
Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway,
Sector 126, Noida, U.P., 201303, India
Tel: +91 120 4261540 / 4261544
www.bisresearch.com

Oncology Precision Medicine Market.pdf

Recommended

Recommended

More Related Content

Similar to Oncology Precision Medicine Market.pdf

Similar to Oncology Precision Medicine Market.pdf (20)

More from BIS Research Inc.

More from BIS Research Inc. (20)

Recently uploaded

Recently uploaded (20)

Oncology Precision Medicine Market.pdf